Novogen Limited (KZIA)
(Delayed Data from NSDQ)
$0.33 USD
-0.01 (-2.42%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $0.32 -0.01 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Novogen Limited [KZIA]
Reports for Purchase
Showing records 1 - 20 ( 47 total )
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Positive Surprise From GBM-AGILE Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Key Clinical Readouts Expected in 2023; Upgrade to Buy with $2.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Reinvestment period with increased R&D focus
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Collaboration may expand utility to combo therapies
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
EVT801 data published in peer-reviewed journal
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
EVT801 data published in peer-reviewed journal
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Q123 cash flows in line with our estimates
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Doubling down on clinical development
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Ambiguity in GBM but pipeline still busy
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Phase 3 GBM Study Misses Interim Milestone; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Paxalisib receives ODD for AT/RT
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Deep dive into childhood brain cancer
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Phase 2 In Line With Expectations; A Catalyst-Rich 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Multiple paxalisib data points expected in Q4
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Multiple paxalisib data points expected in Q4
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
Expanding Pipeline With EVT801 In-License; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Novogen Limited
Industry: Medical - Biomedical and Genetics
New asset to target tumor lymphangiogenesis
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N